13:30-13:40

Welcome & introduction   
Dr Med Béatrice Grabein & Prof. Özlem Kurt Azap

13:40-14:05

Beyond carbapenemases: what are the latest insights on
P. aeruginosa resistance?
Prof. Carlo Tascini

14:05-14:30

Treatment-emergent resistance as an evolving challenge to patient care
Prof. Ryan Shields

14:30-14:55

The PERSEUS study: emerging evidence for cefiderocol in the treatment of CR P. aeruginosa infections
Prof. Alex Soriano 

14:55-15:25

Panel discussion & audience Q&A
All speakers & Chairs 

15:25-15:30

Reflection points & meeting close  
Dr Med Béatrice Grabein & Prof. Özlem Kurt Azap

Fetcroja^® is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.⁷

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Adverse events should also be reported to Shionogi on +44 203 053 4190 or via contact@shionogi.eu. 

Please click this link to access the full Fetcroja^® Summary of Product Characteristics (EN).

Please click this link to access the full Fetcroja^® Summary of Product Characteristics (ES).

Please click this link to access the full Fetcroja^® CIMA Summary of Product Characteristics (ES).

CR, carbapenem-resistant.

1. Cantón R, et al. Expert Rev Anti Infect Ther. 2022:1077-94; 2. Fendian AM, et al. Infect Dis Ther. 2023;12:1205-16; 
3. Bleibtreu A, et al. Microorganisms. 2021;9:282; 4. Meschiari M, et al. JAC Antimicrob Resist. 2021;3:dlab188; 
5. Wicky PH, et al. Antibiotics. 2023:12;991; 6. Bavaro DF, et al. Infect Dis (Lond). 2021;53:206-11;
7. Fetcroja (cefiderocol) Summary of Product Characteristics. Shionogi B.V. December 2023. Available at: www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf [Accessed April 2024].

Dosage and route of administration. The use of Fetcroja is recommended for the treatment of patients with limited treatment options only after consultation with a physician with appropriate experience in the treatment of infectious diseases. Dosage Recommended dose of Fetcroja¹ for patients with a creatinine clearance (CrCl) ≥90 ml/min²: Normal renal function (CrCl ≥90 to <120 ml/min), dose 2 g, every 8 hours, duration in accordance with the site of infection³ Augmented renal clearance (CrCl ≥120 ml/min), dose 2 g, every 6 hours, duration in accordance with the site of infection^{3 1}To be used in combination with antibacterial agents active against anaerobic pathogens and/or Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. ²Calculated using the Cockcroft-Gault formula. ³e.g., for complicated urinary tract infections, including pyelonephritis, and for complicated intra-abdominal infections, the recommended treatment duration is 5 to 10 days. For hospital-acquired pneumonia, including ventilator-associated pneumonia, the recommended treatment duration is 7 to 14 days. Treatment up to 21 days may be necessary. Special populations Renal impairment Recommended dose of Fetcroja for patients with a CrCl <90 ml/min¹: Mild renal impairment (CrCl ≥60 to <90 ml/min) dose 2 g, every 8 hours Moderate renal impairment (CrCl ≥30 to <60 ml/min) dose 1.5 g, every 8 hours Severe renal impairment (CrCl ≥15 to <30 ml/min) dose 1 g, every 8 hours End-stage renal disease (CrCl <15 ml/min) dose 0.75 g, every 12 hours Patients on intermittent haemodialysis² dose 0.75 g, every 12 hours ¹Calculated using the Cockcroft-Gault formula. ²As cefiderocol is removed by haemodialysis, administer cefiderocol as soon as possible after completion of the haemodialysis session on haemodialysis days. Hepatic impairment No dose adjustment is necessary in patients with hepatic impairment (see section 5.2). Elderly population No dose adjustment is necessary (see section 5.2). Paediatric population The safety and efficacy of Fetcroja in children under 18 years of age has not yet been established. No data are available. Method of administration Intravenous route. Fetcroja is administered by intravenous infusion over 3 hours. To consult instructions on reconstitution and dilution of the medicine before administration, see section 6.6. If combined treatment  with another medicinal product and Fetcroja is unavoidable, administration must not occur in the same syringe or in the same infusion solution. It is recommended to adequately flush the intravenous lines between the administration of different medicinal products. DISPENSING AND REIMBURSEMENT CONDITIONS MEDICINAL PRODUCT SUBJECT TO MEDICAL PRESCRIPTION. Hospital diagnosis. Medicinal product included in the pharmaceutical presentation of the Sistema Nacional de Salud. PRESENTATION, NATIONAL CODE AND PRICE. Fetcroja 1 G powder for concentrate for solution for infusion 10 vials. N.C. 728609. PVL 1,500 € PVP VAT: 1,618.15 €. Check Price financed by Sistema Nacional de Salud. 

▼This medicinal product is subject to additional monitoring. Reporting of any suspected adverse reactions associated with this medicinal product is a priority.

This promotional event has been organised and funded by Shionogi B.V.
PP-ES-FDC-0109 | April 2024